` EBS (Emergent BioSolutions Inc) vs S&P 500 Comparison - Alpha Spread

EBS
vs
S&P 500

Over the past 12 months, EBS has underperformed S&P 500, delivering a return of -52% compared to the S&P 500's +17% growth.

Stocks Performance
EBS vs S&P 500

Loading
EBS
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
EBS vs S&P 500

Loading
EBS
S&P 500
Difference
www.alphaspread.com

Performance By Year
EBS vs S&P 500

Loading
EBS
S&P 500
Add Stock

Competitors Performance
Emergent BioSolutions Inc vs Peers

S&P 500
EBS
ABBV
CYTH
AMGN
GILD
Add Stock

Emergent BioSolutions Inc
Glance View

Market Cap
388.6m USD
Industry
Biotechnology

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

EBS Intrinsic Value
25.94 USD
Undervaluation 73%
Intrinsic Value
Price
Back to Top